Hims and Hers Health Inc vs UnitedHealth Group Inc — how do they compare? Hims and Hers Health Inc trades at $30.92 (market cap $6.55B), while UnitedHealth Group Inc trades at $379.3 (market cap $332.96B). The key difference: UnitedHealth Group Inc is far larger — about 50.8× Hims and Hers Health Inc's market cap, and UnitedHealth Group Inc pays a 2.5% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and UnitedHealth Group Inc for 97 Days on average.
| HIMS | UNH | |
|---|---|---|
Market Cap | $6.55B | $332.96B |
Volume | 14,842,814 | 7,273,749 |
Sector | Health | Health |
52-Week High | $62.76 | $436.35 |
52-Week Low | $14.52 | $259.02 |
Typical Hold Time | 21 Days | 97 Days |
Enterprise Value | $7.25B | $374.82B |
Dividend Yield | — | 2.5% |
Signals from Pluang's Aura AI — not financial advice
HIMS stock trades at $28.06, down 5.01% on the day, amid a bearish technical signal and negative earnings surprises. The company reported a net loss of $142 million in 2026, with a negative net income margin of -5.51%, despite revenue growth to $2.6 billion. Multiple securities class action lawsuits filed in October 2026 create significant legal overhang, while analyst consensus remains mixed with a $32.17 price target but only 35% buy ratings.
The outlook is clouded by profitability challenges and legal risks, though revenue growth offers a potential catalyst if margins improve. Investors face substantial downside risk from ongoing litigation and weak earnings, offset by analyst price targets suggesting modest upside from current levels if operational execution improves.
UnitedHealth Group (UNH) trades at $370.95, down 1.34% on the day, amid a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $6.38 versus $4.91 expected, and raised full-year guidance. Revenue for 2025 reached $447.57 billion, though net income margin declined to 2.69%. Analyst consensus remains strongly bullish with an 82.69% buy rating and a $470.11 price target, suggesting significant upside from current levels.
UNH presents a compelling investment case driven by earnings beats, raised 2026 outlook, and strategic initiatives like AI investment in Optum. Key risks include regulatory pressures in healthcare, volatility from Medicare Advantage plan changes, and margin compression. The stock's valuation at a P/E of 23.84 appears reasonable given growth prospects, but investors should weigh execution risks against the positive analyst sentiment and institutional backing.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →